Patents by Inventor Ronald A. Young

Ronald A. Young has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy with apilimod and glutamatergic agents
    Patent number: 11957688
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Grant
    Filed: July 12, 2022
    Date of Patent: April 16, 2024
    Assignee: OrphAl Therapeutics Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
  • APILIMOD COMPOSITIONS AND METHODS OF USE
    Publication number: 20240024332
    Abstract: Provided are compositions and methods related to the use of apilimod alone or in combination with glutamatergic agents or other agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: August 3, 2023
    Publication date: January 25, 2024
    Inventor: Peter Ronald Young
  • COMBINATION THERAPY WITH APILIMOD AND GLUTAMATERGIC AGENTS
    Publication number: 20230069069
    Abstract: Provided are compositions and methods related to the use of apilimod in combination with glutamatergic agents for treating neurological diseases and disorders, and for the treatment of cancer.
    Type: Application
    Filed: July 12, 2022
    Publication date: March 2, 2023
    Applicant: AI Therapeutics, Inc.
    Inventors: Henri Lichenstein, Sean Landrette, Peter Ronald Young, Jonathan M. Rothberg
  • Bicyclic bromodomain inhibitors
    Patent number: 11446306
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: July 28, 2020
    Date of Patent: September 20, 2022
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20210177855
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 17, 2021
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 11026926
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: June 8, 2021
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Bicyclic bromodomain inhibitors
    Patent number: 10772892
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: September 15, 2020
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20190358237
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: June 13, 2019
    Publication date: November 28, 2019
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang LIU, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20190216782
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 18, 2019
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Inhibitors of bromodomains
    Patent number: 10231953
    Abstract: The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: March 19, 2019
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Olesya Kharenko, Peter Ronald Young, Samuel David Brown, Bryan Cordell Duffy, Shuang Liu, Peter Guzzo
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 10226451
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: March 12, 2019
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 10166215
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: January 1, 2019
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • Bicyclic bromodomain inhibitors
    Patent number: 10010556
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: July 3, 2018
    Assignee: Zenith Epigenetics Ltd.
    Inventors: John Frederick Quinn, Bryan Cordell Duffy, Shuang Liu, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, Gregory Steven Wagner, Peter Ronald Young
  • Substituted bicyclic compounds as bromodomain inhibitors
    Patent number: 9999616
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: June 19, 2018
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, John Frederick Quinn, Bryan Cordell Duffy, Ruifang Wang, May Xiaowu Jiang, Gregory Scott Martin, He Zhao, Michael Ellis, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20180161337
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: January 19, 2018
    Publication date: June 14, 2018
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • Heterocyclic compounds as bromodomain inhibitors
    Patent number: 9861637
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: January 9, 2018
    Assignee: Zenith Epigenetics Ltd.
    Inventors: Shuang Liu, Bryan Cordell Duffy, John Frederick Quinn, May Xiaowu Jiang, Ruifang Wang, Gregory Scott Martin, He Zhao, Bruce Francis Molino, Peter Ronald Young
  • Inhibitors of Bromodomains
    Publication number: 20170360760
    Abstract: The present disclosure relates to compounds capable of acting as covalent inhibitors of bromodomains and the therapeutic use of these inhibitors.
    Type: Application
    Filed: December 16, 2015
    Publication date: December 21, 2017
    Inventors: Olesya KHARENKO, Peter Ronald YOUNG, Samuel David BROWN, Bryan Cordell DUFFY, Shuang LIU, Peter GUZZO
  • Biaryl derivatives as bromodomain inhibitors
    Patent number: 9765039
    Abstract: The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
    Type: Grant
    Filed: November 20, 2013
    Date of Patent: September 19, 2017
    Assignee: Zenith Epigenetics Ltd.
    Inventors: David John Fairfax, Gregory Scott Martin, John Frederick Quinn, Bryan Cordell Duffy, Gregory Steven Wagner, Peter Ronald Young
  • NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
    Publication number: 20170216257
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 3, 2017
    Inventors: Shuang Liu, John Frederick QUINN, Bryan Cordell DUFFY, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, He ZHAO, Michael ELLIS, Gregory Steven WAGNER, Peter Ronald YOUNG
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20170216301
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: April 12, 2017
    Publication date: August 3, 2017
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG